Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth
Diabetes mellitus refers to a group of metabolic diseases characterized by chronic hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both (ADA, 2014b). Insulin is a hormone that contributes to the regulation of blood glucose levels by stimulating the uptake of glucose by cells for energy. Consequently, insufficient insulin activity results in chronic hyperglycemia, which is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels.
Market for type 2 diabetes mellitus (T2DM) is expected to grow from $1.92 billion in 2016 to $2.96 billion in 2023, at a compound annual growth rate (CAGR) of 6.3%. This growth will be driven by the rapidly expanding prevalence population, due to increasingly aging populations and sedentary lifestyles, as well as an increase in diagnosis and treatment rates, due to rising disease awareness among the public. The increased uptake of recently approved and emerging branded therapeutics, in favor of lower-cost generic products, will also propel market growth.
Pipeline for T2DM is large, with 609 products at a disclosed stage of development, although the majority of these drugs are at an early stage. About 52% of the pipeline is in the Preclinical stage, while 17% is in the Discovery stage. Though 28% of the pipeline is in clinical development, only 2% is in the Pre-registration stage. The late-stage pipeline contains a high proportion of products from established drug classes, with improved dosing regimens and administration routes compared with currently marketed products. By 2023, Novo Nordisk’s OG-217SC (oral semaglutide) is expected to be in the market.
The top-selling drugs presently - Januvia, Victoza, Novolog, and Invokana - are expected to remain dominant within the disease cluster and are all - along with many other top-selling products - indicated for T2DM. However, three of the anticipated top 10 best-selling drugs of 2023 will be new to the South-East Asia market.
The report “Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth” covers epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and co-morbidities and complications of type 2 diabetes mellitus (T2DM),
In depth, this report provides the following -
Companies mentioned in this report:
- Provides an overview of the T2DM marketed products landscape, including product profiles of key marketed products and heatmaps that compare the safety and efficacy parameters of the various drugs.
- Analyzes the T2DM pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target. The chapter concludes with an analysis of promising pipeline molecules, including product profiles and a heatmap that compares the efficacy and safety data for the various drugs.
- Provides detailed analysis of recent clinical trials in T2DM by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
- Supplies forecasts for the T2DM market, including epidemiology, treatment usage patterns, pricing, and market size, for the 2016-2023 period. The eight South-East Asia markets are covered and data are presented at a country level.
- Provides detailed analysis of key market drivers and barriers for T2DM in South-East Asia markets.
- Describes the major deals that have taken place in the global T2DM market in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value. Licensing and co-development deals by region are also included.
Pfizer, Theracos, Merck & Co., Sanofi.
The current T2DM market in South-East Asia contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor.
- What are the competitive advantages of the existing novel drugs?
There are over 609 active pipeline molecules, with most of the late-stage investigational drug candidates featuring improved dosing regimens and administration routes compared with currently marketed products and combination therapies.
- Which classes of novel drugs are most prominent in the pipeline?
- Is there potential for pipeline molecules to address unmet needs within the T2DM market?
Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 62.1%, with the overall attrition rate for T2DM standing at 88.3%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2016-2023 forecast period, the T2DM therapeutics market in South-East Asia is expected to increase in value at a CAGR of 6.3%, from $1.92 billion to over $2.96 billion.
- Which markets make the most significant contribution to the regional market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?
Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.
- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
Reasons to buy
- Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed product landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
- Discover trends in licensing and co-development deals concerning T2DM products, and identify the major strategic consolidations that have shaped the commercial landscape.